BREAKING: Cognitive researchers confirm that leaving half-drunk mugs of coffee, water glasses, and soda cans scattered across every room in the house isn't "sloppiness"—it is a documented visual processing quirk called "Salience Habituation."
If you live with someone who leaves a trail of 6 abandoned drinks behind them every day, here is what is actually happening inside their brain: 1/5
@FelixWellero Unlike drugs (and competitors Siegel and Encantor) durAVR did the highest risk patients first. STS score for the paradigm is lower than the STS score for EFS. We should expect better results in PARADIGM than what we are going to see this week, which I also expect to be excellent.
Different populations and measurements limit direct comparison; superiority remains unproven.
References:
Garg et al. EHJ–Valvular and Structural Heart Disease, 2026. doi:10.1093/ehjvshd/xwag011
Chau et al. JACC, 2020. doi:10.1016/j.jacc.2020.03.042
$AVR Paradigm Powered Secondary Review
8) LV mass index regression vs Sapien- Superiority
The most difficult to model. DurAVR showed rapid LV mass regression (~18%) at 6 months—broadly comparable in magnitude to older-generation SAPIEN results at 1 year.
$AVR Paradigm Powered Secondary Review
7) Indexed aortic flow reversal ratio vs Sapien- Superiority
My base case favors DurAVR, with indexed flow reversal ~2.5–2.6 %/cm² at 1 year if its 6-month performance holds. Early paired MRI data showed ~33% improvement from baseline.
LFLG aortic stenosis are among the sickest patients. Notice the heart remodels over several years leading to improved outcomes.
$AVR has shown rapid LV mass regression following durAVR placement in EFS; Garg P, et al Eur Heart J Valv Struct Heart Dis. 2026;2(1).
Flow matters.
REBOOT-PARADOX. No significant survival difference does not establish no benefit.
Among survivors, symptom improvement and HF rehospitalization favored immediate TAVR.
For $AVR, the question is whether DurAVR’s physiologic flow translates into better outcomes.
Does early TAVR improve survival in symptomatic paradoxical low-flow, low-gradient aortic stenosis?
REBOOT-PARADOX (n=120): death 29% vs 37% on medical therapy (P=.60). Symptoms and readmissions favored TAVR; trial stopped early.
@JuMehilli
New in #JACC: https://t.co/WcsKzPpNIi
$AVR Paradigm Powered Secondary Review
6) Mean aortic valve gradient in patients under 75 vs Sapien- Superiority
My base case for DurAVR’s mean gradient at 1 year in patients under 75 comes in ~2 mmHg below SAPIEN, assuming 100% Ultra RESILIA controls.
The assumed advantage is 2.4 mmHg in small annuli and 2.0 mmHg in medium annuli. Any mix of those two groups produces an estimated difference between 2.0 and 2.4 mmHg. DurAVR’s 100-patient small-annulus cohort was 78% female. SMART trial was 86.7% female.
$AVR $AVR Paradigm Powered Secondary Review
5) Mean aortic valve gradient in women vs Sapien- Superiority
My base case for DurAVR’s mean gradient in women at 1 year comes in ~2 mmHg below SAPIEN, assuming 100% Ultra RESILIA controls.